文献速递免疫规划卫生政策与健康促进

加拿大成人中21价肺炎球菌结合疫苗的成本效果分析

Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada.
PubMed 文献 · Vaccine · 2025-03-06

该研究采用静态队列模型,评估PCV21相较于加拿大现行成人疫苗接种建议的成本效果,涵盖33岁、50岁和65岁人群队列,从卫生系统和社会视角计算终身增量成本效果比(ICER),以2023年加元/QALY计、贴现率1.5%。结果显示,对当前推荐接种PCV20的人群,PCV21在每QALY 5万加元阈值下具有成本效果,且在PCV21血清型更流行时多数情景下优于PCV20;对未推荐接种结合疫苗的人群,使用高价结合疫苗相较不接种具有成本效果,最优疫苗取决于PCV20和PCV21血清型所致IPD的比例。

要点

  • 对当前推荐PCV20的成人,PCV21在每QALY 5万加元阈值下具有成本效果。
  • PCV21血清型更流行时,多数情景下PCV21优于PCV20。
  • 未推荐结合疫苗人群,高价结合疫苗相较不接种具有成本效果。

核心结论

  • 在部分人群中,PCV21可能具有成本效果,取决于PCV20和PCV21覆盖的IPD血清型流行率。

研究设计与样本

  • 采用静态队列模型,估算33岁、50岁和65岁人群队列的终身增量成本效果比(ICER),以2023年加元/QALY计、贴现率1.5%,从卫生系统和社会视角分析。
  • 主要分析使用2022年IPD病例的血清型分布;补充分析纳入儿童接种的间接效应,并使用2015至2019年IPD血清型分布。

主要发现

  • 对当前推荐接种PCV20的人群(65岁及以上、50-64岁有额外IPD风险因素、18-49岁有免疫抑制状况),PCV21在每QALY 5万加元阈值下具有成本效果,且在PCV21血清型更流行时多数情景下优于PCV20。
  • 当PCV20血清型同等或更流行时,结果对间接效应和血清型替换的假设更敏感。
  • 对未推荐接种结合疫苗的人群(50-64岁无额外IPD风险因素、18-49岁有慢性疾病或无家可归人群),使用高价结合疫苗相较不接种具有成本效果,最优疫苗取决于目标人群中PCV20和PCV21血清型所致IPD的比例。
  • 多数情景下结果对疫苗价格敏感。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A 21-valent pneumococcal conjugate vaccine (PCV21) was recently authorized in Canada to protect adults against invasive pneumococcal disease (IPD). OBJECTIVE: To assess the cost-effectiveness of PCV21 compared to current Canadian vaccination recommendations for adults of different age and risk groups. METHODS: We used a static cohort model to estimate lifetime incremental cost-effectiveness ratios (ICERs), in 2023 Canadian dollars per quality-adjusted life year (QALY), discounted at 1.5 %, in population cohorts aged 33 (midpoint of the 18-49 year age group), 50, and 65 years from the health system and societal perspectives. The primary analysis used 2022 serotype distributions for IPD cases. Additional analyses incorporated indirect effects from pediatric vaccination and used IPD serotype distributions from 2015 to 2019, to explore the impact of changes over time observed in some age groups. RESULTS: For population groups currently recommended to receive PCV20 in Canada (65 years and older, 50-64 years with additional risk factors for IPD, or 18-49 years with immunocompromising conditions), PCV21 was cost-effective at a $50,000 per QALY threshold and dominated PCV20 in most scenarios when PCV21 serotypes were more prevalent. When PCV20 serotypes were equally or more prevalent than PCV21 serotypes, results were more sensitive to assumptions about indirect effects and serotype replacement. For groups not currently recommended a conjugate vaccine (50-64 years without additional IPD risk factors and 18-49 years with chronic medical conditions or unhoused populations), use of a higher-valency conjugate vaccine was a cost-effective intervention compared to no vaccination, with the optimal vaccine dependent on the proportion of IPD attributable to PCV20 and PCV21 serotypes in the population of interest. Results were sensitive to vaccine price in most scenarios. INTERPRETATION: The use of PCV21 may be cost-effective in some populations, depending on the prevalence of IPD serotypes covered by PCV20 and PCV21.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ximenes R, Simmons AE, Gebretekle GB, et al. Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada. Vaccine. 2025. PMID: 40054141. doi:10.1016/j.vaccine.2025.126985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。